Amorphical Announces Full Patient Enrollment in Phase 2 FDA Clinical Trial of AMOR-1 for the Treatment of Hypoparathyroidism

Phase 2AMOR-1Positive

AI Analysis

Summary

Amorphical announced full patient enrollment in its Phase 2 FDA clinical trial of AMOR-1, a nano-amorphous calcium carbonate treatment for hypoparathyroidism designed to maintain serum calcium levels using half the elemental calcium dose of conventional treatments.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Full patient enrollment completed

Importance:6/10

Sentiment:

0.60

Phase 2enrollment completionhypoparathyroidismnano-amorphous calcium carbonateclinical trial

Read the original article

Published by PR Newswire Pharma on July 28, 2026 12:30 PM

Read Original